These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 29846965

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN.
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J.
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [Abstract] [Full Text] [Related]

  • 7. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M.
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A.
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [Abstract] [Full Text] [Related]

  • 9. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
    Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, Guerin A.
    J Dermatolog Treat; 2018 Feb; 29(1):24-31. PubMed ID: 28608740
    [Abstract] [Full Text] [Related]

  • 10. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P, Halliday A, Aassi M, Subramanian S, Jain M, Griffiths CEM.
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [Abstract] [Full Text] [Related]

  • 11. Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service.
    Puig L, Notario J, Jiménez-Morales A, Moreno-Ramírez D, López-Ferrer A, Gozalbo I, Prades M, Lizán L, Blanch C.
    J Dermatolog Treat; 2017 Nov; 28(7):623-630. PubMed ID: 28784002
    [Abstract] [Full Text] [Related]

  • 12. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, Yiu ZZN, Griffiths CEM, Burden AD, BADBIR Study Group.
    JAMA Dermatol; 2018 May 01; 154(5):581-588. PubMed ID: 29590279
    [Abstract] [Full Text] [Related]

  • 13. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, Papavassilis C, Mpofu S.
    J Drugs Dermatol; 2015 Aug 01; 14(8):821-33. PubMed ID: 26267726
    [Abstract] [Full Text] [Related]

  • 14. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
    Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, Amato D, Nikaï E, Yang FE, Gordon KB.
    JAMA Dermatol; 2016 Jun 01; 152(6):661-9. PubMed ID: 26953848
    [Abstract] [Full Text] [Related]

  • 15. Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.
    Alpalhão M, Duarte J, Diogo R, Vandemeulebroecke M, Ortmann CE, Kasparek T, Filipe P.
    BioDrugs; 2022 Nov 01; 36(6):781-789. PubMed ID: 36334236
    [Abstract] [Full Text] [Related]

  • 16. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S, Foster SA, Burge R, Amato D, Schacht A, Zhu B, Hartz S, Leonardi C.
    J Med Econ; 2017 Dec 01; 20(12):1224-1230. PubMed ID: 28760056
    [Abstract] [Full Text] [Related]

  • 17. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
    Puig L, Augustin M, Blauvelt A, Gottlieb AB, Vender R, Korman NJ, Thaçi D, Zhao Y, Gilloteau I, Sherif B, Williams N, Guana A, Lebwohl MG.
    J Am Acad Dermatol; 2018 Apr 01; 78(4):741-748. PubMed ID: 29066271
    [Abstract] [Full Text] [Related]

  • 18. Continued treatment with secukinumab is associated with high retention or regain of response.
    Augustin M, Thaci D, Eyerich K, Pinter A, Radtke M, Lauffer F, Mrowietz U, Gerdes S, Pariser D, Lebwohl M, Sieder C, Melzer N, Reich K.
    Br J Dermatol; 2020 Jan 01; 182(1):67-75. PubMed ID: 30972746
    [Abstract] [Full Text] [Related]

  • 19. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
    Blauvelt A, Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S.
    J Eur Acad Dermatol Venereol; 2017 Oct 01; 31(10):1693-1699. PubMed ID: 28602039
    [Abstract] [Full Text] [Related]

  • 20. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
    Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B.
    J Dermatolog Treat; 2011 Jun 01; 22(3):138-43. PubMed ID: 21254886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.